Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. to Develop Next-Generation iPSC Pipeline for Its ImmCelz® Immunotherapy Platform

0

PHOENIX, June 15, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, of Urology, Neurology and Orthopedics, today announced that the Company has signed an agreement with Greenstone Biosciences Inc. in Palo Alto, California for the development of a human induced pluripotent stem cell (iPSC) pipeline for the company’s ImmCelz® Platform. This project will be identified as iPScelzMT for future reference.

Creative <a class=Medical Technology Holdings, Inc. Logo (PRNewsfoto/Creative Medical Technology Hol)” src=”https://s.yimg.com/ny/api/res/1.2/sBvivB23jkvCA8cvGja9oQ–/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwMg–/https://s.yimg.com/uu/api/res/1.2/TtiEG1Oj2M0dgziuZ.U7zQ–~B/aD01ODt3PTQwMDthcHBpZD15dGFjaHlvbg–/https://media.zenfs.com/en/prnewswire.com/069602b783b716fa6fa0d2e26c256833″/>

Creative Medical Technology Holdings, Inc. Logo (PRNewsfoto/Creative Medical Technology Hol)

dr. Joseph C. Wu, co-founder of Greenstone Biosciences, comments, “This is an excellent collaboration that translates our expertise in iPSC technology to accelerate therapies that improve patient care – from bench to bedside. Dr. Wu is director of the Stanford Cardiovascular Institute and Simon H. Stertzer, MD, professor of medicine and radiology at Stanford University.

Timothy WarbingtonPresident and CEO of the company, said, “We are excited to complement and expand our current work with the addition of Dr. Joseph Wu and the green stone team from the Alexandria Center for Life Sciences (ACLS). Greenstone brings extensive experience in the development of iPSC and related technologies. In combination with the ongoing work at University of Miamiwe believe our ImmCelz® platform has tremendous potential to improve patient outcomes across multiple indications, including stroke, type I diabetes, heart disease, liver disease and kidney disease. »

Human iPScs are genetically reprogrammed to differentiate into a wide range of human cell and tissue types, possess the ability to proliferate almost indefinitely in culture, and represent a unique source of cells that could be used to replace those lost to damage. or diseases. Beyond the therapeutic benefits offered by iPSC, the next generation of iPScelzMT pipeline for ImmCelz® will enable large-scale production and sustainability, while helping to reduce long-term manufacturing costs.

About ImmCelz®

ImmCelz®, which is protected by trade secrets and published US patents, uses adult stem cells from qualified donors to impart specific properties to the patient’s immune cells. Once the cells harvested from the patient have been incubated with the company’s cell-free reprogramming “cocktail”, the cells are returned to the patient. These “supercharged” cells subsequently “educate” other cells of the immune system to stop attacking the body, while preserving the ability to attack foreign pathogens.

About Greenstone Biosciences

Greenstone Biosciences, Inc. (Palo Alto, California) is a biotechnology company co-founded by Joseph C. WuMD, PhD and Chao Jade, JD, MPH. The biotech company specializes in clinical genomics, iPSC technology, AI/ML and drug development. green stone has extensive knowledge and expertise in the generation of patient-derived human iPSCs and differentiates into many cell types for disease modeling and drug discovery. green stone Walden Catalyst Venture (WCV) Chairman Lip-Bu Tan is a long-term strategic partner. Mr. Tan considers “this to be a wonderful and strategic partnership with CELZ”. For more information, please visit www.greenstonebio.com.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics. For more information about the Company, please visit www.creativemedicaltechnology.com.

Forward-looking statements

This press release may contain forward-looking statements, including, but not limited to, comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements relate to future events and conditions and, therefore, involve risks and uncertainties. Actual results may differ materially from those currently anticipated in these statements. See periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.

Quote

View original content to download multimedia: https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-agreement-with-greenstone-biosciences-inc-for-development-of-a -next-generation-ipsc-pipeline-for-its-immunotherapy-platform-immcelz-301568167.html

SOURCE Creative Medical Technology Holdings, Inc.


Source link

Share.

Comments are closed.